ASND Rule 144 Notice: 5,000 ADS via Warrant Exercise Listed with Merrill Lynch

Rhea-AI Filing Summary

Insider notice of proposed sale under Rule 144 for Ascendis Pharma A/S (ASND). The filing shows 5,000 American Depositary Shares acquired via warrant exercise and to be sold through Merrill Lynch on NASDAQ with an aggregate market value of $965,000. The filer previously sold 9,375 ADS for $1,826,403.05 earlier in August. The filing discloses the acquisition method (warrant exercise), the broker, the number of shares outstanding (60,454,589) and that payment for the exercised ADS was in cash. The signer also represents they have no undisclosed material adverse information about the issuer.

Positive

• Disclosure compliance: The filer properly submitted a Rule 144 notice documenting acquisition method, broker, and planned sale.
• Clear acquisition path: Shares were acquired via warrant exercise with cash payment, reducing ambiguity about provenance of securities.

Negative

• Insider selling: The filer has executed recent sales (9,375 ADS) and proposes another sale (5,000 ADS), which some investors may view negatively despite immaterial size.

Insights

Securities Analyst

TL;DR: Small insider sales following a warrant exercise; disclosure aligns with Rule 144 requirements and appears routine.

The 5,000 ADS sale (aggregate value $965k) stems from a warrant exercise and will be brokered by Merrill Lynch on NASDAQ. A prior sale of 9,375 ADS for $1.826M is disclosed for the past three months. Relative to the 60.45 million shares outstanding, these transactions are immaterial on a share-count basis. Primary considerations are compliance with resale rules and potential short-term supply impact. No new operational or financial details about the issuer are provided in this filing.

Corporate Governance Expert

TL;DR: The filing provides standard Rule 144 transparency; transactions are documented but do not disclose company fundamentals.

The notice documents the source of shares (warrant exercise by Ascendis Pharma A/S) and confirms cash payment on exercise. The filer attests to absence of undisclosed material information, which is a required legal representation. This filing is procedural and governance-focused; it confirms disclosure obligations were met but does not signal corporate governance changes or material events affecting investors.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	5000	965000.00	60454589	08/29/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	08/29/2025	Warrant exercise	Ascendis Pharma A/S			5000	08/29/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Michael Wolff Jensen Ascendis Pharma A/S HELLERUP G7 00000	American Depositary Shares	08/15/2025	9375	1826403.05

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Ascendis Pharma (ASND) disclose?

The form discloses a proposed sale of 5,000 ADS valued at $965,000, acquired via warrant exercise, to be brokered by Merrill Lynch on NASDAQ; it also lists a prior sale of 9,375 ADS for $1,826,403.05.

Who is the seller named in the Form 144 for ASND?

The filing names Michael Wolff Jensen as the person whose account the securities are to be sold.

How many Ascendis Pharma shares are outstanding according to the filing?

The filing reports 60,454,589 shares (American Depositary Shares) outstanding.

How were the 5,000 ADS acquired?

The 5,000 ADS were acquired on 08/29/2025 through a warrant exercise from Ascendis Pharma A/S, with payment in cash.

Does the filing indicate any undisclosed material information about Ascendis Pharma?

By signing the notice, the filer represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.